The nanoparticle albumin-bound paclitaxel formulation (Abraxane) received Food and Drug Administration (FDA) approval in 2005, achieving significantly higher tumor response rates (33% vs. 19%) and longer time to tumor progression (23.0 vs. 16.9 weeks) compared to standard paclitaxel in metastatic breast cancer patients [210]. Here, ALB is linked to neoplasm.